Asthma therapy - deCODE genetics

Drug Profile

Asthma therapy - deCODE genetics

Alternative Names: MAP3K9 kinase inhibitors - deCODE

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator deCODE genetics
  • Class Gene therapies
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 03 May 2006 deCODE has completed a phase II trial in asthma in Iceland
  • 18 May 2005 Phase-II clinical trials in Asthma in Iceland (unspecified route)
  • 17 Dec 2004 deCODE genetics has formed a drug development agreement with an undisclosed company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top